# Liver Biopsy Market

> Liver Biopsy Market Research Report Information By Type (Percutaneous, Transjugular, Laparoscopic), Indication (Nonalcoholic Fatty Liver Disease, Chronic Hepatitis B Or C), End User (Hospitals & Clinics, Diagnostic Centers) -Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.51%
- **2024:** $ 0.92 Billion
- **2025:** $ 0.99 Billion
- **2035:** $ 2.04 Billion
- **Key Players:** F. Hoffmann-La Roche Ltd (CH), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (DE), Becton, Dickinson and Company (US), Medtronic plc (IE), Hologic, Inc. (US), PerkinElmer, Inc. (US)

**Report ID:** MRFR/MED/4087-HCR · **Pages:** 110 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/liver-biopsy-market-5534

---

## Market Summary

## **Liver Biopsy Market Overview**

Liver Biopsy Market Size was valued at USD 0.84 Billion in 2023. The Liver Biopsy industry is projected to grow from USD 0.92 Billion in 2024 to USD 1.67 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.92% during the forecast period (2024 - 2032). Liver biopsy is a procedure for obtaining samples from kidney tissue for analysis. Liver biopsy is used to diagnose various liver diseases such as nonalcoholic fatty liver disease, chronic hepatitis B or C, autoimmune hepatitis, and alcoholic liver disease.

Along with the diagnosis it is also used to monitor the effect of treatment and determine whether the kidney transplant is working well or not. It consists of mainly two types; percutaneous biopsy, transjugular, and laparoscopic. In a percutaneous biopsy, a needle is inserted into the kidney through the skin, while in the surgical biopsy, an incision is made in the skin near the liver to take a tissue sample for examination.

According to the Centers for Disease Control and Prevention (CDC), 3.9 million adults were diagnosed with liver disease in the U.S.

Increasing prevalence of liver diseases and increasing number of biopsy procedures and diseases are the major drivers for the growth of the the liver biopsy market. Furthermore, rising demand for new techniques for diagnosis of chronic and the need for better diagnostic and treatment methods drive the growth of the the liver biopsy market. Major players in the developed countries lead the global market by offering new products and services to the developing countries and emerging economies. However, the high cost of diagnostic devices and instruments may hinder the liver biopsy market growth during the forecast period.

## **Liver Biopsy Market Segment Insights**

The global liver biopsy market is segmented on the basis of type, indication, and end user.

### **Liver Biopsy Diagnosis Insights**

On the basis of diagnosis, the liver biopsy market is segmented into [percutaneous](../../../reports/percutaneous-coronary-intervention-market-3166), transjugular, and laparoscopic biopsy.

### **Liver Biopsy Indication Insights**

On the basis of indication, the liver biopsy market is segmented into the nonalcoholic fatty liver disease, chronic [hepatitis B](../../../reports/hepatitis-b-treatment-market-7817) or C, autoimmune hepatitis, alcoholic liver disease, and others.

### **Liver Biopsy End User Insights**

Based on the end user, the liver biopsy market is segmented into hospitals & clinics, tertiary care centers, urology centers, and others.

**Liver Biopsy Market Regional Analysis**

The Americas liver biopsy market is expected to exhibit extensive growth owing to technological advancement in the healthcare sector and increasing number of patient population suffering from liver diseases such as alcoholic liver disease and the high healthcare spending, and increasing government support for research & development will further boost the the liver biopsy market growth. Additionally, liver disease is one of the major cause of mortality and morbidity in the Americas, thus boosting the market growth. As per the data from (CDC), in 2016, 38,170 deaths occurred due to liver diseases in the U.S.

Additionally, 6.10% of the adults were diagnosed with liver diseases in the U.S. alone. As per the World Health Organisation (WHO), about 35 million people in the world die of chronic diseases, while 46% of the mortality is due to chronic diseases. According to National statistics in the U.K, liver diseases is the fifth most common cause of death across the globe. Liver diseases are the second leading cause of mortality amongst all digestive diseases in the U.S.

In Europe, Germany, France, and the U.K are the major markets for liver biopsy. The market growth in the European region is attributed to increased use of diagnostic services in tertiary care centers, research and development activities in the field of chronic disease diagnostics, and the emergence of new market players in the medical device industry. 

Asia Pacific is expected to be the fastest growing kidney biopsy market across the globe owing to the vast progress of healthcare industries in major economies such as China, Japan, and India along with rising prevalence of chronic diseases such as chronic hepatitis B or C, and alcoholic liver disease. Japan holds a major share of the regional market due to the availability of technology, increasing healthcare spending, and increasing government initiatives for research. India is the hub of the patient population with various chronic diseases in the Asia Pacific region exhibiting extensive growth opportunities in the market.

Rapidly developing healthcare technology sector and increasing healthcare expenditure also drive the the liver biopsy market. Furthermore, increasing demand for quality devices in the healthcare is expected to boost the use of advanced equipment, which, in turn, may speed up the growth of the market in the region.

The Middle East & Africa hold the least share of the global market due to limited availability of medical facilities. The United Arab Emirates, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market whereas, the African region is expected to witness a moderate growth.

**Liver Biopsy Market Key Players**

** Intended Audience**

## Market Drivers

### Increasing Prevalence of Liver Diseases

The rising incidence of liver diseases, including hepatitis and cirrhosis, is a primary driver of the Liver Biopsy Market. According to recent data, liver diseases affect millions worldwide, leading to a heightened demand for diagnostic procedures. This trend is particularly evident in regions with high rates of viral hepatitis, where liver biopsies are essential for assessing disease progression. The need for accurate diagnosis and monitoring of liver conditions propels the market forward, as healthcare providers seek reliable methods to evaluate liver health. Furthermore, the increasing burden of non-alcoholic fatty liver disease (NAFLD) is contributing to the demand for liver biopsies, as clinicians require precise information to guide treatment decisions. As awareness of liver health continues to grow, the Liver Biopsy Market is likely to expand to meet the needs of patients and healthcare systems.

### Rising Demand for Personalized Medicine

The shift towards personalized medicine is emerging as a significant driver in the Liver Biopsy Market. As healthcare moves away from a one-size-fits-all approach, the need for tailored treatment plans based on individual patient profiles becomes increasingly important. Liver biopsies play a crucial role in this paradigm shift, providing essential information about liver pathology that informs personalized treatment strategies. The ability to assess liver tissue at a molecular level allows clinicians to make more informed decisions regarding therapy options, particularly in the context of liver cancer and chronic liver diseases. This trend is likely to enhance the demand for liver biopsies, as healthcare providers seek to optimize patient outcomes through individualized care. Consequently, the Liver Biopsy Market is poised for growth as the focus on personalized medicine continues to gain traction.

### Regulatory Support for Diagnostic Procedures

Regulatory support for diagnostic procedures is an essential factor driving the Liver Biopsy Market. Governments and health organizations are increasingly recognizing the importance of accurate diagnostic tools in managing liver diseases. This recognition has led to the establishment of guidelines and frameworks that promote the use of liver biopsies as a standard practice in clinical settings. Additionally, regulatory bodies are working to streamline the approval processes for new biopsy technologies, encouraging innovation and adoption within the market. As a result, healthcare providers are more likely to incorporate liver biopsy procedures into their diagnostic protocols, thereby increasing demand. The ongoing support from regulatory agencies is expected to foster a favorable environment for the Liver Biopsy Market, ultimately enhancing patient outcomes through improved diagnostic accuracy.

### Growing Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is a vital driver of the Liver Biopsy Market. As countries prioritize the enhancement of healthcare systems, the availability of advanced diagnostic tools, including liver biopsy procedures, is expected to increase. This trend is particularly pronounced in emerging economies, where governments and private sectors are collaborating to improve healthcare access and quality. The establishment of specialized liver clinics and diagnostic centers is likely to facilitate the adoption of liver biopsy techniques, thereby expanding the market. Furthermore, increased funding for research and development in liver disease diagnostics is anticipated to lead to innovative solutions that enhance the efficacy of liver biopsies. As healthcare infrastructure continues to evolve, the Liver Biopsy Market is expected to benefit from improved access to diagnostic services and enhanced patient care.

### Technological Advancements in Biopsy Techniques

Technological innovations in biopsy techniques are significantly influencing the Liver Biopsy Market. The development of minimally invasive procedures, such as ultrasound-guided liver biopsies, has improved patient outcomes and reduced complications. These advancements not only enhance the accuracy of liver disease diagnosis but also increase patient comfort, leading to higher acceptance rates of biopsy procedures. Moreover, the integration of imaging technologies, such as MRI and CT scans, with biopsy techniques allows for more precise targeting of liver lesions. This synergy between technology and clinical practice is expected to drive market growth, as healthcare providers adopt these advanced methods to improve diagnostic accuracy. As the industry continues to evolve, the introduction of new technologies may further transform the landscape of liver biopsies, making them safer and more effective.

## Future Outlook

The Liver Biopsy Market is projected to grow at a 7.51% CAGR from 2025 to 2035, driven by advancements in diagnostic technologies and increasing prevalence of liver diseases.

**New opportunities:**

- Development of minimally invasive biopsy devices for outpatient settings. Integration of AI-driven analytics for enhanced diagnostic accuracy. Expansion of telemedicine platforms for remote biopsy consultations.

By 2035, the Liver Biopsy Market is expected to achieve substantial growth, reflecting evolving healthcare demands.

## Segment Insights

### By Type: Percutaneous Biopsy (Largest) vs. Laparoscopic Biopsy (Fastest-Growing)

In the Liver Biopsy Market, the percutaneous biopsy segment dominates in terms of market share, primarily due to its minimally invasive nature and widespread acceptance among healthcare professionals. This method accounts for a significant portion of liver biopsy procedures, as it is generally well-tolerated by patients and offers quick recovery times. Conversely, the transjugular biopsy segment, while essential, holds a smaller market share, appealing primarily to patients with specific medical conditions that make other methods less viable. The growth trends in the liver biopsy segment are driven by increasing awareness of liver diseases and the need for accurate diagnosis. The laparoscopic biopsy is emerging as the fastest-growing technique, thanks to advancements in technology and surgical methods that enhance safety and effectiveness. These trends indicate an ongoing evolution in biopsy techniques, with telemedicine and robotic-assisted procedures also gaining traction in the coming years.

Percutaneous Biopsy (Dominant) vs. Transjugular Biopsy (Emerging)

Percutaneous biopsy is recognized as the dominant approach in the liver biopsy market, favored for its simplicity and lower risk of complications. It typically involves the insertion of a needle through the skin to obtain liver tissue samples, making it suitable for outpatients. In contrast, transjugular biopsy, while less common, offers advantages for patients with underlying conditions such as coagulopathy or ascites, as it provides access to the liver via the jugular vein. Despite its emerging status, the transjugular approach is gaining prominence, particularly in specialized settings, due to the increased focus on patient safety and precision in liver disease diagnosis.

### By Indication: Nonalcoholic Fatty Liver Disease (Largest) vs. Chronic Hepatitis B or C (Fastest-Growing)

The liver biopsy market, categorized by indication, reveals a significant distribution in favor of nonalcoholic fatty liver disease (NAFLD), which has emerged as the largest segment due to the rising prevalence of obesity and metabolic disorders. In contrast, chronic hepatitis B and C are witnessing increased attention, promising substantial growth as diagnostic and treatment methods advance. Other segments like autoimmune hepatitis and alcoholic liver disease also contribute to the market dynamics but do not match the scale of NAFLD or the growth rate of hepatitis cases.

Nonalcoholic Fatty Liver Disease (Dominant) vs. Chronic Hepatitis B or C (Emerging)

Nonalcoholic fatty liver disease (NAFLD) remains the dominant indication in the liver biopsy market, attributed to its link with widespread lifestyle-related health issues. NAFLD's growing prevalence necessitates effective diagnosis, thus fueling demand for liver biopsies. On the other hand, chronic hepatitis B and C are emerging as fast-growing segments, primarily driven by increased awareness about viral hepatitis and advancements in treatment options. While NAFLD is primarily linked to lifestyle factors, hepatitis B and C cases are driven by infectious pathogens, representing diverse underlying causes for liver damage. Both segments have distinct clinical implications, influencing their management strategies and the overall landscape of liver health care.

### By End User: Hospitals & Clinics (Largest) vs. Tertiary Care Centers (Fastest-Growing)

The Liver Biopsy Market shows a diverse distribution among its end users, with Hospitals & Clinics leading the way as the dominant segment. They account for a significant portion of the market share due to their extensive resources and increasing patient referrals for liver-related ailments. Tertiary Care Centers, while currently smaller in share, are experiencing rapid growth driven by specialized treatments and advanced technologies attracting more patients requiring liver biopsy procedures.

Hospitals & Clinics (Dominant) vs. Tertiary Care Centers (Emerging)

Hospitals & Clinics have solidified their position as the dominant players in the Liver Biopsy Market by providing comprehensive care that includes biopsy procedures among a wide array of hospital services. These facilities are equipped with advanced diagnostic tools and have a steady influx of patients, making them vital in managing liver diseases. In contrast, Tertiary Care Centers are emerging as significant contributors to the market due to their specialized focus and capacity to handle complex cases. Their cutting-edge technologies and expert teams cater to higher-tier patients, allowing for innovative biopsy techniques and treatments, thus driving their growth within this sector.

## Regional Market Share Analysis

### North America : Leading Innovation and Demand

The North American liver biopsy market is driven by increasing prevalence of liver diseases, advancements in biopsy techniques, and supportive regulatory frameworks. The region holds the largest market share at approximately 45%, with the U.S. being the primary contributor due to its advanced healthcare infrastructure and high demand for diagnostic procedures. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring safety and efficacy in liver biopsy procedures.

In North America, the competitive landscape is characterized by the presence of major players such as Abbott Laboratories, Thermo Fisher Scientific, and Medtronic. These companies are continuously innovating and expanding their product offerings to meet the growing demand. The U.S. market is particularly strong, with a focus on minimally invasive techniques and enhanced patient outcomes, positioning it as a leader in The Liver Biopsy.

### Europe : Emerging Market with Potential

Europe is witnessing a significant rise in the liver biopsy market, driven by increasing awareness of liver diseases and advancements in diagnostic technologies. The region holds the second-largest market share at around 30%. Countries like Germany and the UK are leading the charge, supported by favorable healthcare policies and a growing emphasis on early diagnosis and treatment of liver conditions. Regulatory bodies are also promoting innovative biopsy techniques, enhancing market growth.

The competitive landscape in Europe features key players such as Siemens Healthineers and F. Hoffmann-La Roche Ltd, who are investing in research and development to introduce cutting-edge solutions. The presence of well-established healthcare systems in countries like France and Italy further supports market expansion. Collaborative efforts among healthcare providers and technology firms are expected to drive innovation and improve patient outcomes in liver biopsy procedures.

### Asia-Pacific : Rapidly Expanding Market

The Asia-Pacific region is emerging as a significant player in the liver biopsy market, driven by rising incidences of liver diseases and increasing healthcare expenditure. The market is expected to grow rapidly, with countries like China and India leading the way. The region's market share is estimated to be around 15%, supported by government initiatives aimed at improving healthcare access and quality. Regulatory bodies are also working to streamline approval processes for new diagnostic technologies, further boosting market potential.

In Asia-Pacific, the competitive landscape is evolving, with both local and international players vying for market share. Companies like Hologic, Inc. and PerkinElmer, Inc. are expanding their presence in the region, focusing on innovative solutions tailored to local needs. The growing awareness of liver health and the push for advanced diagnostic methods are expected to drive significant growth in the liver biopsy market across this diverse region.

### Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa region presents untapped potential in the liver biopsy market, driven by increasing healthcare investments and rising awareness of liver diseases. The market share is currently around 10%, with countries like South Africa and the UAE showing promising growth trends. Government initiatives aimed at enhancing healthcare infrastructure and access to diagnostic services are expected to catalyze market expansion in the coming years.

The competitive landscape in this region is characterized by a mix of local and international players. Companies are focusing on establishing partnerships and collaborations to enhance their market presence. The growing emphasis on improving healthcare quality and access in countries like Kenya and Nigeria is likely to drive demand for advanced liver biopsy solutions, positioning the region for future growth.

## Competitive Benchmarking

The Liver Biopsy Market is currently characterized by a dynamic competitive landscape, driven by advancements in diagnostic technologies and an increasing prevalence of liver diseases globally. Key players such as F. Hoffmann-La Roche Ltd (CH), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Roche, for instance, focuses on integrating digital solutions into its diagnostic processes, while Abbott emphasizes the development of minimally invasive biopsy techniques. These strategies collectively foster a competitive environment that prioritizes technological advancement and patient-centric solutions.

In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The Liver Biopsy Market appears moderately fragmented, with several players vying for market share. The collective influence of major companies shapes the market structure, as they engage in strategic collaborations and mergers to enhance their operational capabilities and expand their geographical reach.

In August 2025, F. Hoffmann-La Roche Ltd (CH) announced a partnership with a leading telehealth provider to enhance remote diagnostic capabilities for liver biopsies. This strategic move is likely to improve patient access to diagnostic services, particularly in underserved regions, thereby expanding Roche's market footprint and reinforcing its commitment to innovative healthcare solutions.

In September 2025, Abbott Laboratories (US) launched a new line of biopsy devices designed to minimize patient discomfort and improve diagnostic accuracy. This product introduction not only reflects Abbott's focus on innovation but also positions the company to capture a larger share of the market by addressing the growing demand for less invasive procedures. The emphasis on patient experience is expected to resonate well with healthcare providers and patients alike.

In October 2025, Thermo Fisher Scientific Inc. (US) unveiled a new AI-driven platform aimed at enhancing the analysis of liver biopsy samples. This technological advancement signifies a shift towards integrating artificial intelligence in diagnostic processes, potentially increasing the efficiency and accuracy of liver disease diagnoses. Such innovations may provide Thermo Fisher with a competitive edge in a market that increasingly values precision and speed in diagnostics.

As of October 2025, current competitive trends in the Liver Biopsy Market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing service delivery. Looking ahead, it is anticipated that competitive differentiation will increasingly pivot from price-based strategies to a focus on technological innovation, reliability in supply chains, and the overall enhancement of patient care experiences.

## Report Scope

| MARKET SIZE 2024 | 0.92(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.9891(USD Billion) |
| MARKET SIZE 2035 | 2.04(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.51% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd (CH), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (DE), Becton, Dickinson and Company (US), Medtronic plc (IE), Hologic, Inc. (US), PerkinElmer, Inc. (US) |
| Segments Covered | Type |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the Liver Biopsy Market. |
| Key Market Dynamics | Technological advancements in imaging and needle techniques enhance accuracy and safety in liver biopsy procedures. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Liver Biopsy Market by 2035?**
A: The Liver Biopsy Market is projected to reach a valuation of 2.04 USD Billion by 2035.

**Q: What was the market valuation of the Liver Biopsy Market in 2024?**
A: In 2024, the Liver Biopsy Market was valued at 0.92 USD Billion.

**Q: What is the expected CAGR for the Liver Biopsy Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Liver Biopsy Market during the forecast period 2025 - 2035 is 7.51%.

**Q: Which companies are considered key players in the Liver Biopsy Market?**
A: Key players in the Liver Biopsy Market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, and Thermo Fisher Scientific Inc.

**Q: What are the primary types of liver biopsy procedures and their market values?**
A: The primary types of liver biopsy procedures include percutaneous biopsy valued at 0.9 USD Billion and transjugular biopsy valued at 0.7 USD Billion.

**Q: What indications are driving the Liver Biopsy Market?**
A: Indications driving the market include chronic hepatitis B or C, projected to reach 0.7 USD Billion by 2035.

**Q: How do hospitals and clinics contribute to the Liver Biopsy Market?**
A: Hospitals and clinics are expected to contribute significantly, with a market value projected at 0.9 USD Billion by 2035.

**Q: What is the market value for laparoscopic biopsy procedures?**
A: The market value for laparoscopic biopsy procedures is projected to reach 0.44 USD Billion by 2035.

**Q: What role do tertiary care centers play in the Liver Biopsy Market?**
A: Tertiary care centers are projected to have a market value of 0.5 USD Billion by 2035.

**Q: What is the market outlook for autoimmune hepatitis in the Liver Biopsy Market?**
A: The market outlook for autoimmune hepatitis indicates a potential growth to 0.25 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/liver-biopsy-market-5534*